ArticleEJHaem2025
Flow Cytometry Analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myelodysplastic syndrome progress to acute myeloid leukemia: new insights and updates.Frontiers in immunology · 2026Review
- Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluates the prognostic value of bone marrow-derived mesenchymal stem cells (MSCs) in predicting the progression of Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML). Methods: MSC-like cells were analyzed using flow cytometry in a cohort of 49 MDS patients, including transformed and non-transformed groups. Results: A non-hematopoietic CD13-bright cell population, enriched for MSC markers CD105 and CD90, was identified in 80% of patients at diagnosis. Elevated of these MSC-like cells were significantly associated with earlier progression to leukemia and reduced overall survival. Multivariate analysis confirmed MSC content as an independent predictor of leukemia transformation. Conclusion: MSC-like cell content at MDS diagnosis may serve as a novel biomarker of predicting malignant transformation to AML. Further validation in larger cohorts and better phenotypic characterization of this cell population are needed. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.